Abstract
Objective
To investigate the expression status of Thy-1 in malignant cancerous tissues and to evaluate whether Thy-1 could be a potential tumor marker.
Methods
Immunohistochemistry method was used to examine Thy-1 expressions in different malignant tumor tissues. We used a monoclonal antibody specific for Thy-1 and the indirect Catalysis Signal Amplification method. With the help of tissue microarray (TMA), we examined expression the status of Thy-1 in 1451 different types of malignant tumor tissues, 144 normal tissues and benign lesions.
Results
All the malignant tumor cells were grouped as one group (malignant cells group) and normal or benign tumor tissue cells as another group (normal cells group). Among the entire 1451 malignant cases group, positive Thy-1 expression with diffuse and strong staining was observed in 734 (734/1451; 50.59%) cases. In the benign cases only 6 chronic cervicitis cases showed weak staining for Thy-1. All the normal tissue showed negative staining. One-way ANVOA analysis showed F value between these two groups was 147.229 (P<0.0001).
Conclusion
A significantly stronger expression of Thy-1 in malignant tumors was observed. Special overexpression of Thy-1 in malignant tumors suggests that Thy-1 might be a potential novel tumor marker with respect to cancer progression. Chronic cervicitis has some relationship with cervix carcinoma. When it develops into atypical hyperplasia, it will be a precancerous lesion for cervix carcinoma. In this research we found weak staining for Thy-1 in chronic cervicitis lesion, so Thy-1 may play a crucial role in carcinogenesis for cervix carcinoma. The research about the relationship between Thy-1 expressions in cancer cells and in precancerous lesion will provide some clues to understand the mechanism for carcinogenesis process.
Similar content being viewed by others
References
Leyton L, Schneider P, Labra CV, et al. Thy-1 binds to integrin beta(3) on astrocytes and triggers formation of focal contact sites [J]. Curr Biol 2001; 11:1028–1038.
Reif AE, Allen JM. The AKR thymic antigen and its distribution in leukemias and nervous tissues [J]. J Exp Med 1964; 120:413–433.
Dalchau R, Fabre JW. Identification and unusual tissue distribution of the canine and human homologues of Thy-1 (theta) [J]. J Exp Med 1979; 149:576–591.
Koumas L, Smith TJ, Feldon S, et al. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes [J]. Am J Pathol 2003; 163:1291–1300.
Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis [J]. Faseb J 2006; 20: 1045–1054.
Rege TA, Hagood JS. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses [J]. Biochim Biophys Acta 2006; 1763:991–999.
Saalbach A, Wetzel A, Haustein UF, et al. Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium [J]. Oncogene 2005; 24: 4710–4720.
Zeng LQ, Peng ZL. Growth inhibitory effects of THY1 gene on epithelial ovarian cancer SKOV3 cells [J]. Nan Fang Yi Ke Da Xue Xue Bao (in Chinese) 2007; 27:84–87, 91.
Chen JF, et al. Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance [J]. Zhonghua Yi Xue Za Zhi (in Chinese) 2005; 85:1921–1925.
McKenzie JL, Dalchau R, Fabre JW. Biochemical characterisation and localization in brain of a human brain-leucocyte membrane glycoprotein recognised by a monoclonal antibody [J]. J Neurochem 1982; 39:1461–1466.
Reif AE, Allen JM. Mouse nervous tissue iso-antigens [J]. Nature 1966; 209:523.
Rege TA, Pallero MA, Gomez C, et al. Thy-1, via its GPI anchor, modulates Src family kinase and focal adhesion kinase phosphorylation and subcellular localization, and fibroblast migration, in response to thrombospondin-1/hep I [J]. Exp Cell Res 2006; 312:3752–3767.
Wang X, Wiesinger J, Beard J, et al. Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome [J]. J Neurol Sci 2004; 220:59–66.
He HT, Naquet P, Caillol D, et al. Thy-1 supports adhesion of mouse thymocytes to thymic epithelial cells through a Ca2(+)-independent mechanism [J]. J Exp Med 1991; 173:515–518.
Hueber AO, Raposo G, Pierres M, et al. Thy-1 triggers mouse thymocyte apoptosis through a bcl-2-resistant mechanism [J]. J Exp Med 1994; 179:785–796.
Mason JC, Yarwood H, Tárnok A, et al. Human Thy-1 is cytokine-inducible on vascular endothelial cells and is a signaling molecule regulated by protein kinase C [J]. J Immunol 1996; 157:874–883.
Haeryfar SM, Hoskin DW. Thy-1: more than a mouse pan-T cell marker [J]. J Immunol 2004; 173:3581–3588.
Saalbach A, Arnhold J, Lessig J, et al. Human Thy-1 induces secretion of matrix metalloproteinase-9 and CXCL8 from human neutrophils [J]. Eur J Immunol 2008; 38: 1391–1403.
Abeysinghe HR, Cao Q, Xu J,et al. THY1 expression is associated with tumor suppression of human ovarian cancer [J]. Cancer Genet Cytogenet 2003; 143:125–132.
Lung HL, Bangarusamy DK, Xie D,et al. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma [J]. Oncogene 2005; 24:6525–6532.
Abeysinghe HR, Pollock SJ, Guckert NL, et al. The role of the THY1 gene in human ovarian cancer suppression based on transfection studies [J]. Cancer Genet Cytogenet 2004; 149:1–10.
Saalbach A, Hildebrandt G, Haustein UF, et al. The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1-positive microvascular endothelial cells [J]. Microvasc Res 2002; 64: 86–93.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a grant from the Foundation of Health Bureau of Beijing (No.2003-049)
Rights and permissions
About this article
Cite this article
Chen, Jf., Lu, Ap., Wu, N. et al. Special expression of Thy-1 in different malignant tumors. Chin. J. Cancer Res. 22, 73–79 (2010). https://doi.org/10.1007/s11670-010-0073-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11670-010-0073-0